BeiGene Incentive Plan: 147 Employees Get RSUs, Capital Steady

BeOne Medicines Ltd. (the "Company") maintained its total authorized/registered share capital at $231,146.38 as of November 30, 2025. The company's ordinary shares reported a balance of 2,311,463,847 authorized/registered shares with a par value of $0.0001 per share. There were no increases or decreases in authorized share capital during the month.

The number of issued ordinary shares (excluding treasury shares) also remained stable at 1,425,622,549. Additionally, the Company's RMB shares saw no movement in issued shares, holding at 115,055,260. The Company’s share option schemes showed minor adjustments with 490,581 new options granted and 530,036 cancelled, resulting in total funds raised from exercise of options of $13,718,019.5.

The Company operates with a capital band ranging from $138,687.83 to $231,146.38, allowing its board of directors to adjust share capital until April 28, 2029, under Swiss law. The report highlights that 33,278,466 shares of the 133,000,000 ordinary shares held by BG NC 2, Ltd were issued to satisfy equity awards and are considered outstanding as of November 30, 2025.